PARTHENON THERAPEUTICS is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as many cancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on rigorous, groundbreaking research, we are designing a portfolio of drug candidates to treat the right patients at the right time. Parthenon recently closed its Series A financing for $65 million. Come join our dynamic team!
We are seeking a self-motivated individual who desires to have a direct impact on the science within our early stage, fast-paced, and dynamic biotech. The candidate will have well-documented scientific expertise in molecular and cellular tumor biology and an abiding interest in drug discovery. This scientist will lead the preclinical in vivo
pharmacology efforts across Parthenon's drug discovery pipeline, develop and implement project-specific scientific strategies, investigate efficacy and PK/PD relationships of lead compounds, perform detailed mechanism of action studies internally and with external partners, and ensure completion of activities according to project timelines. This role is highly collaborative, closely works with the translational science team, supports regulatory and IP functions, and has the opportunity to be part of the decision making within the discovery and clinical teams. Role & Responsibilities:
- Develop preclinical in vivo pharmacology strategies across Parthenon's drug candidate pipeline and target identification platform
- Identify and collaborate with internal and external stakeholders and CROs for plan implementation
- Design and execute in vivo studies in syngeneic mouse tumor models to determine antitumor efficacy, pharmacodynamic effects, and pharmacokinetics of drug candidates
- Apply cutting-edge methods to uncover novel insights into target biology at the cancer cell/stromal cell interface and characterize mechanisms of tumor immune exclusion.
- Closely collaborate with Translational Science group to support biomarker efforts.
- Analyze, interpret, and document study results; contribute to regulatory and IP filings as needed.
- When appropriate, publish high-quality research relevant to the mission of Parthenon.
- PhD and a minimum of 7-9 years of post-graduate experience in preclinical pharmacology, of which at least 3 years in the biopharmaceutical industry, preferably as project lead in oncology
- Excellent knowledge of human and mouse tumor models in oncology and immune-oncology, and methods to characterize antitumor responses, with emphasis on immune cell characterization, signaling, and stromal biology.
- Expertise in designing and executing pharmacology studies to determine drug antitumor effects and identify pharmacologically active doses in PK/PD studies
- Experience in downstream analytical methods, including TIL profiling, IHC/IF, RNAseq, and analysis of drug PK and serum biomarkers by ELISA or MSD
- Direct experience interacting with and/or managing CROs is required.
- Outstanding collaborative and project leadership skills, with the ability to rapidly adapt research plans to deliver data in support of internal needs and project timelines
- Independent, self-motivated, and innovative with the ability to excel in a goal-oriented, nimble, and fast-moving team environment.
- Effective communicator of data and results to biologists, clinicians, and business partners.